{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:35:20Z","timestamp":1769837720128,"version":"3.49.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2254640","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T07:05:59Z","timestamp":1694070359000},"page":"1134-1144","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma"],"prefix":"10.1080","volume":"26","author":[{"given":"Matthew","family":"Matasar","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Masaquel","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"S. Ho","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aino","family":"Launonen","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen D.","family":"Ng","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fox","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Hossain","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers\/US Oncology, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148948"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01725"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158406"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0057"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030538"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1901721"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00339-1"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.04.1245"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"e_1_3_8_23_1","unstructured":"Microsoft Corporation. Microsoft Excel. 2016 [cited 2023 June 28]. https:\/\/office.microsoft.com\/excel"},{"key":"e_1_3_8_24_1","unstructured":"Centers for Medicare & Medicaid Services. ASP Drug Pricing Files. 2023. [cited 2023 June 28]. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2023-asp-drug-pricing-files"},{"key":"e_1_3_8_25_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule search. 2022 [cited 2023 Aug 08]. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/overview.aspx"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1734592"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000469"},{"key":"e_1_3_8_28_1","unstructured":"US Bureau of Labor Statistics. How do retirement plans for private industry and state and local government workers compare? 2023 [cited 2023 July 04]. https:\/\/www.bls.gov\/opub\/btn\/volume-12\/how-do-retirement-plans-for-private-industry-and-state-and-local-government-workers-compare.htm"},{"key":"e_1_3_8_29_1","unstructured":"US Bureau of Labor Statistics. Average weekly hours and overtime of all employees on private nonfarm payrolls by industry sector seasonally adjusted. 2023 [cited 2023 Mar 05]. https:\/\/www.bls.gov\/news.release\/empsit.t18.htm"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.9716"},{"key":"e_1_3_8_31_1","unstructured":"US Bureau of Labor Statistics. News release. 2023 [cited 2023 Mar 7]. https:\/\/www.bls.gov\/news.release\/pdf\/empsit.pdf"},{"key":"e_1_3_8_32_1","volume-title":"Healthcare cost and utilization project (HCUP)","author":"HCUP National Inpatient Sample (NIS)","year":"2017","unstructured":"HCUP National Inpatient Sample (NIS). Healthcare cost and utilization project (HCUP). Rockville (MD): Agency for Healthcare Research and Quality; 2017 [cited 2023 June 28]. www.hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"e_1_3_8_33_1","unstructured":"US Food and Drug Administration. POLIVY \u00ae US Prescribing Information. 2023 [cited 2023 July 14]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761121s008lbl.pdf"},{"key":"e_1_3_8_34_1","unstructured":"US Bureau of Labor Statistics. CPI for all urban customers medical care in U.S. city average. 2023 [cited 2023 May 05]. https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM"},{"key":"e_1_3_8_35_1","unstructured":"Genentech Inc. Data on file."},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.021"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0490"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-021-00260-z"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"issue":"2","key":"e_1_3_8_40_1","first-page":"1","article-title":"National vital statistics reports: from the centers for disease control and prevention, national center for health statistics, national vital statistics system","volume":"71","author":"Arias E","year":"2022","unstructured":"Arias E, Xu J, Tejada-Vera B, et\u00a0al. National vital statistics reports: from the centers for disease control and prevention, national center for health statistics, national vital statistics system. Natl Vital Stat Rep. 2022;71(2):1\u201318.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.0765"},{"key":"e_1_3_8_42_1","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et\u00a0al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"e_1_3_8_43_1","unstructured":"National Institute of Health and Care Excellence (NICE) Guidance.\u00a0Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. 2023 [cited 2023 Apr 06]. https:\/\/www.nice.org.uk\/guidance\/ta874\/resources\/polatuzumab-vedotin-in-combination-for-untreated-diffuse-large-bcell-lymphoma-pdf-82613673152197"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006578"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31814848f1"},{"key":"e_1_3_8_47_1","unstructured":"Kite Pharma Inc. YESCARTA \u00ae U.S. prescribing Information. 2022 [2023 May 05]. https:\/\/www.fda.gov\/media\/108377\/download"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016624"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162980"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00478"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_8_52_1","unstructured":"National Institute of Health and Care Excellence (NICE) Guidance. Tisagenlecleucel for treating relapsed or refractory diffuse large\u00a0B-cell lymphoma after 2 or more systemic therapies. 2019 [cited 2023 May 02]. https:\/\/www.nice.org.uk\/guidance\/ta567\/resources\/tisagenlecleucel-for-treating-relapsed-or-refractory-diffuse-large-bcell-lymphoma-after-2-or-more-systemic-therapies-pdf-82607087377861"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.51.5866"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy203"},{"key":"e_1_3_8_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.77.9124"},{"key":"e_1_3_8_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956"},{"key":"e_1_3_8_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7537"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2254640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:05:00Z","timestamp":1701943500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2254640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2254640"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2254640","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}